These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 29628780)

  • 1. Emerging treatment options for
    Ursem C; Atreya CE; Van Loon K
    Gastrointest Cancer; 2018; 8():13-23. PubMed ID: 29628780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines.
    Grothey A; Fakih M; Tabernero J
    Ann Oncol; 2021 Aug; 32(8):959-967. PubMed ID: 33836264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pathologic features correlated with rare favorable survival in patients with
    Morris V; Kee B; Overman M; Dasari A; Raghav K; Johnson B; Parseghian C; Wolff RA; Garg N; Eng C; Kopetz S
    J Gastrointest Oncol; 2022 Apr; 13(2):647-656. PubMed ID: 35557581
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Ros J; Baraibar I; Sardo E; Mulet N; Salvà F; Argilés G; Martini G; Ciardiello D; Cuadra JL; Tabernero J; Élez E
    Ther Adv Med Oncol; 2021; 13():1758835921992974. PubMed ID: 33747149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the therapy of BRAF
    Jin Z; Sinicrope FA
    Expert Rev Anticancer Ther; 2019 Sep; 19(9):823-829. PubMed ID: 31455117
    [No Abstract]   [Full Text] [Related]  

  • 6. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS.
    Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA
    Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
    Roviello G; D'Angelo A; Petrioli R; Roviello F; Cianchi F; Nobili S; Mini E; Lavacchi D
    Transl Oncol; 2020 Sep; 13(9):100795. PubMed ID: 32470910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Retrospective Analysis of Treatment Pathways in Patients With BRAF
    Gerger A; Eisterer W; Fuxius S; Bastian S; Koeberle D; Welslau M; Sanoyan DA; Maas C; Uhlig J; Fenchel K; Greil R; VON DER Heyde E; Agocs GR; Weide R; Schwager M; Reichenbach F; Modest DP; Fritsch R
    Anticancer Res; 2022 Oct; 42(10):4773-4785. PubMed ID: 36191968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yes-activated protein promotes primary resistance of
    Su M; Zhan L; Zhang Y; Zhang J
    J Gastrointest Oncol; 2021 Jun; 12(3):953-963. PubMed ID: 34295548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Evolutionary Landscape of Treatment for
    Mauri G; Bonazzina E; Amatu A; Tosi F; Bencardino K; Gori V; Massihnia D; Cipani T; Spina F; Ghezzi S; Siena S; Sartore-Bianchi A
    Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33406649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF
    Trivieri N; Pracella R; Cariglia MG; Panebianco C; Parrella P; Visioli A; Giani F; Soriano AA; Barile C; Canistro G; Latiano TP; Dimitri L; Bazzocchi F; Cassano D; Vescovi AL; Pazienza V; Binda E
    J Exp Clin Cancer Res; 2020 Dec; 39(1):285. PubMed ID: 33317591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF-V600E and microsatellite instability prediction through CA-19-9/CEA ratio in patients with colorectal cancer.
    Kasi PM; Kamatham S; Shahjehan F; Li Z; Johnson PW; Merchea A; Colibaseanu DT
    J Gastrointest Oncol; 2020 Apr; 11(2):236-241. PubMed ID: 32399264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H).
    Goldstein J; Tran B; Ensor J; Gibbs P; Wong HL; Wong SF; Vilar E; Tie J; Broaddus R; Kopetz S; Desai J; Overman MJ
    Ann Oncol; 2014 May; 25(5):1032-8. PubMed ID: 24585723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer.
    Grassi E; Corbelli J; Papiani G; Barbera MA; Gazzaneo F; Tamberi S
    Front Oncol; 2021; 11():601722. PubMed ID: 34249672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer.
    Lee HM; Morris V; Napolitano S; Kopetz S
    Oncology (Williston Park); 2019 Jun; 33(6):206-11. PubMed ID: 31219603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma.
    Räsänen K; Dang KX; Mustonen H; Ho TH; Lintula S; Koistinen H; Stenman UH; Haglund C; Stenman J
    Mol Oncol; 2018 Feb; 12(2):224-238. PubMed ID: 29193645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies.
    Morris VK
    Curr Colorectal Cancer Rep; 2019 Apr; 15(2):53-60. PubMed ID: 31762713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Evolving Treatment Landscape in
    Tabernero J; Ros J; Élez E
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-10. PubMed ID: 35503983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report.
    Callebout E; Ribeiro SM; Laurent S; De Man M; Ferdinande L; Claes KBM; Van der Meulen J; Geboes KP
    BMC Cancer; 2019 Jun; 19(1):567. PubMed ID: 31185985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.